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The Gastrointestinal Microbiota; A key regulator in Visceral Pain 
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Gastrointestinal Microbiota 
The human gut harbours a complex and dynamic microbial ecosystem. We each harbour a 
unique microbiota signature of bacteria, archaea, yeasts, single-celled eukaryotes, as well as 
helminth parasites and viruses, including bacteriophage 1. Numbering approximately 100 
trillion, these microorganisms have an estimated collective mass of 1–2 kg 2, approximately 
the same weight as the human brain. Genes within the human gut microbiota significantly 
outnumber host human genes and are capable of producing a plethora of centrally-acting 
compounds, influencing virtually all aspects of human physiology and biology 3. 
The microbiome-gut-brain axis is a complex bi-directional system including the central 
nervous system (CNS), the neuroendocrine and neuroimmune systems, the autonomic nervous 
system, the enteric nervous system (ENS), and, of course, the gut microbiome. Through 
endocrine, immune and neuropeptide/neurotransmitter systems, the microbiota can relay 
information about health status of the gut. This in turn can profoundly impact on neuronal 
signalling in the brain and thus impact on emotional systems and behavioural response 3,4. This 
may be true for visceral pain, as the facilitation or inhibition of pain processing is mediated at 
a central level, while ascending visceral afferents are mediated through the spinal cord, as a 
consequence of primary visceral nociceptor activation. 
Visceral Pain 
Pain is a multimodal experience combining a discriminative sensory component with a 
complex graded emotional response. This physiological survival facility is inherent to all 
sentient organisms to protect against potential or existing tissue damage. While the anatomical 
pathways and signalling mechanisms involved in somatic/musculoskeletal pain (skin and deep 
tissue) are relatively well defined, the mechanisms underlying visceral pain (internal organs) 
and its treatment are proving a difficult target for therapeutic intervention. Visceral pain is 
believed to affect up to 40% of the population at some stage in their lifetime and is commonly 
associated with an aching or throbbing sensation with varying degrees of discomfort, and often 
difficult to localise to a precise anatomical region.  
 
Functional gastrointestinal disorders (FGID’s) including functional dyspepsia, irritable bowel 
syndrome (IBS) and infant colic represent the more common forms of visceral pain. IBS alone 
affects an estimated 10-15% of the population in developed countries with an estimated 
economic burden to healthcare systems in the billions (Canavan et al. 2014). Other commonly 
reported malaises include myocardial infarction (heart attack), dysmenhorrea, appendicitis, 
bladder pain and pelvic pain.  
 
The perception of gastrointestinal pain and discomfort involves complex mechanisms. These 
include peripheral sensitization of sensory nerves and, at a central level, regulation of thalamic 
and corticolimbic signalling pathways. Of interest, there is substantial overlap in the brain areas 
underlying visceral pain and those that are involved in the processing of psychological stress, 
a key predisposing factor for visceral hypersensitivity. 
 
Visceral Pain Pathways 
After an event such as visceral injury, stress or infection; the nociceptive information coding 
for visceral pain, is propagated from the site of origin to the spinal cord, and then through 
ascending spinal pathways to the brain. Nociceptors in the viscera respond to mechanical 
stimulation such as distension or pressure, tissue damage and chemical stimulation as a 
consequence of inflammation, infection or ischaemia. These receptors are localised on bare 
nerve endings containing transient receptor potential (TRP) channels that detect tissue damage 
or injury. Chemicals that activate TRP channels include globulin, protein kinases, arachidonic 
acid, prostaglandins, histamine, nerve growth factor, substance P, calcitonin gene-related 
peptide, serotonin, acetylcholine, ATP and changes in pH 5.  
At the dorsal horn of the spinal cord, biochemically active agents including substance P, 
glutamate, aspartate, vasoactive intestinal peptide (VIP), cholecystokinin (CCK), somatostatin, 
calcitonin gene-related peptide (CGRP) and galanin are released from the nerve terminals of 
the visceral primary afferents to propagate the nociceptive signal to second order neurons. 
Under normal physiological conditions, these neurons are under ‘gated’ control. However, 
once a certain threshold of stimulation is surpassed, these neurons are no longer suppressed 
and the nociceptive information coding for general location and intensity projects to 
supraspinal sites. The two major ascending pain pathways in mammals are the spinothalamic 
and the spinoparabrachial tracts, which encode the sensory-discriminatory and affective 
aspects of pain respectively 6. Once the nociceptive information has been processed, the 
descending pathways (from brain to spinal cord) can exert an inhibitory or facilitatory effect 
on the sensation of pain. Interestingly, the supraspinal and peripheral anatomical regions 
involved in facilitation and inhibition of nociception often overlap. Sensitization of receptors 
in these anatomical loci as a consequence of repeated or prolonged activation can often lead to 
chronic, repeated and often unpredictable bouts of visceral pain. Thus by targeting key 
bioactive chemicals or receptor systems on these sensory afferent neurons, the sensation of 
visceral pain could be significantly ameliorated. 
The Gastrointestinal Microbiota and Visceral Pain 
At the source, the sensitisation of primary afferent nociceptors may lead to visceral 
hypersensitivity in FGIDs. A number of different receptor types are involved in the process of 
peripheral sensitization including the TRPV family, proteinase activated receptors, 
cholecystokinin receptors, serotonin receptors, cannabinoid receptors, as well as an array of 
ion channels including ATP-gated ion channels, voltage-gated sodium and calcium channels, 
and acid-sensing ion channels 7. The gastrointestinal microbiota can activate these receptors 
directly or indirectly through immune responses at the mucosal surface during infection, 
inflammation and autoimmunity, formyl peptides and protease release, polyunsatturated fatty 
acid (PUFA) release, SCFA (short chain fatty acid) production, neurotransmitter production 
and hormone secretion 8. Gastrointestinal microbiota can also stimulate the release of the 
body’s natural pain-suppressing biomolecules including opioids from innate neutrophils and 
monocytes, endocannabinoids from colonic tissue, as well as other pain modulators 9 including 
monoamines. Microbial metabolites can also influence epigenetic mechanisms, by altering 
substrate concentrations or by direct inhitibiton of enzymatic machinery in epigenetic pathways 
10. However, the extent to which these mechanisms either individually or collectively has in 
the aetiology of FGIDs remains unaddressed. 
 
From a physiological perspective relevant to IBS visceral sensitivity; stress can influence gut 
motility, alter gastroinestinal secretions and exacerbate intestinal permeability – all of which 
can have a negative impact on gastroinestinal microbiota number and diversity. While most 
individuals are routinely exposed to intermittent stress, some are more susceptible and this can 
lead to stress-related disorders and related comorbidities. It may well be that this maladaptive 
stress response is mediated by a lack or overexpression of  specific gastrointestinal microbiota. 
 
Interestingly, adverse early-life events are linked with a maladaptive stress response and might 
increase the vulnerability of individuals to visceral sensitivity and other stress-related disorders 
later in life. While it is difficult to conclusively attribute early life stress and associated changes 
in gastrointestinal microbiota with the presentation of visceral sensitivity in later life in 
humans, the use of animals to establish this link has been very informative. 
 
Empirical Evidence for Gastrointestinal Microbiota Involvement in Visceral Pain 
Response  
 
Animals raised in a sterile environment (germ-free mice) have an exaggerated stress response 
and reduced perception of pain following different inflammatory stimuli. In naïve animals, 
antibiotic-mediated depletion of gastrointestinal microbiota decreased visceral pain-related 
response in mice and rats; and early-life exposure to antibiotics predisposed animals to visceral 
sensitivity in adulthood 11. Recently, faecal matter from IBS patients characterised by 
hypersensitivity to colorectal distension was transplanted to germ-free rats, and the response to 
colorectal distension was enhanced in these animals 12. Accumulating empirical evidence 
supports a role for positively influencing gastrointestinal microbiota with probiotic treatment 
in the treatment of visceral sensitivity and other ailments – provided vagus nerve integrity was 
maintained (Bravo et al., 2011).  
 
In contrast to the provocative preclinical evidence for a role for gut microbiota in visceral pain, 
clinical studies remain inconclusive with a large ‘non-responder’ population in many probiotic 
trials. Anecdotal evidence suggests that antibiotics may be useful in treating bacterial infections 
that may be contributing to the discomfort and pain associated with FGID and inflammation, 
however further research is required to confirm these assertions. It is clear that longitudinal, 
placebo-controlled, double-blind studies with whole-system analysis 13,14 and complimentary 
brain imaging are necessary to integrate central, peripheral and behavioural alterations before, 
during and after treatment of visceral pain. 
 
Summary 
A growing body of preclinical and clinical evidence supports a relationship between the 
complexity and diversity of the microorganisms that inhabit our gut (human gastrointestinal 
microbiota) and health status. Under normal homeostatic conditions this microbial population 
helps maintain intestinal peristalsis, mucosal integrity, pH balance, immune priming and 
protection against invading pathogens. Furthermore, these microbes can influence centrally 
regulated emotional behaviour through mechanisms including microbially-derived bioactive 
molecules (amino acid metabolites, short chain fatty acids, neuropeptides and 
neurotransmitters), mucosal immune and enteroendocrine cell activation, as well as vagal nerve 
stimulation. 
 
Changes to the microbial environment, as a consequence of illness, stress or injury can lead to 
a broad spectrum of physiological and behavioural effects locally including a decrease in gut 
barrier integrity, altered gut motility, inflammatory mediator release, as well as nociceptive and 
distension receptor sensitisation. Centrally mediated events including hypothalamic-pituitary-
adrenal (HPA) axis, neuroinflammatory events and neurotransmitter systems are concomitantly 
altered. Thus, both central and peripheral pathways associated with pain manifestation and 
perception are altered as a consequence of the microbiota-gut-brain axis imbalance. 
 
The dogmatic approach of antibiotic treatment in the latter century for the treatment of many 
diseases and conditions, has undergone a radical change. We are 90% microbe, and pragmatism 
suggests that we manipulate this ecosystem for the treatment of various ailments, stress 
dysfunction and affective disorders, including the alleviation of visceral sensitivity.  
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